Video Series

Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies.

Subcutaneous cancer therapy cuts chair time and IV needs, but brings site reactions, volume limits, and policy hurdles clinics must solve.

Real-world evidence and claims data compare amyloidosis therapies, linking outcomes and symptom burden to total cost of care.

In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists explore the key clinical and economic considerations that drive therapy selection across the three available ATTR-CM treatments. Dr. Alexander opens by emphasizing shared decision-making as a foundational principle, noting that in the absence of head-to-head data, patient preferences carry significant weight alongside clinical judgment. He outlines several practical factors influencing treatment choice, including route of administration, as vutrisiran is a quarterly injection given in a healthcare setting, acoramidis is a twice-daily oral pill, and tafamidis is a once-daily oral pill, each presenting distinct advantages depending on patient circumstances such as pill burden or transportation access.

Subcutaneous cancer therapy trims chair time and costs, but volume limits and reactions matter—learn how clinics streamline workflows.

Experts decode NSCLC PD‑L1 trials, when immunotherapy alone works, why crossover matters, and who still benefits from adding chemotherapy.

Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety.

Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival.

Clinicians weigh dual immunotherapy vs monotherapy in metastatic NSCLC, comparing CheckMate 227 and POSEIDON efficacy, PD‑L1 subsets, and toxicity.

In the final episode, Near-Term Priorities for Transforming Clinical Practice in IgA Nephropathy, the panelist explored the following critical question: What do you hope to see in the next 1–2 years in terms of clinical practice change?

This episode, titled Rethinking KDIGO Guidance and Payer Models in the Era of Targeted IgA Nephropathy Therapies, features expert nephrologists discussing the following critical questions: What updates to KDIGO will likely need to be made in view of these novel therapies being approved? How should payers and health systems think differently about treating this disease?

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.

Experts weigh neoadjuvant vs adjuvant immunotherapy in resectable lung cancer, balancing PD‑L1, pCR, surgery timing, and toxicity.

In Advocacy Strategies and the Expanding Role of Novel Therapies in IgA Nephropathy, our panel delves into the following critical questions: What strategies can clinicians use to advocate for access or navigate step edits? How might real-world data and ongoing registries (like RaDaR) support broader adoption and payer confidence?

In this episode, Overcoming Access Barriers and Step-Edit Challenges in IgA Nephropathy Care, the panelists explore the following questions: What barriers exist to real-world use, particularly around payer policies or access? Many plans require a systemic steroid step-edit; why might this be inappropriate for IgAN?

Experts weigh lung cancer perioperative immunotherapy trials, debating adjuvant nivolumab, ctDNA guidance, and chemo choices versus pembrolizumab data.

Experts discuss the promising advancements in HER2-mutant lung cancer treatments, emphasizing the importance of molecular testing and clinical trials.

How EGFR, ALK and PD-L1 biomarker results shape neoadjuvant lung cancer therapy—and what CheckMate-816 means for survival.

Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the pivotal CheckMate 816 trial, which established neoadjuvant nivolumab plus chemotherapy as a standard-of-care option based on improved pathologic response and event-free survival outcomes.

Experts discuss how treatment strategies for NSCLC differ between resectable and metastatic disease, emphasizing a multimodal, curative approach in early-stage cancer versus personalized systemic therapy focused on disease control and survival in advanced stages.

Emerging HER2-targeted therapies in lung cancer highlight the importance of real-world data and survival metrics for patient outcomes and treatment access.

Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.

This episode examines the barriers to accessing HER2-targeted therapies for non-small cell lung cancer (NSCLC) and strategies to overcome them. The discussion highlights the importance of aligning with payer requirements and clinical guidelines, such as those from NCCN, to facilitate insurance approval of recently FDA-approved HER2-targeted treatments.

Experts discuss the FDA's Accelerated Approval Program, emphasizing its role in providing earlier access to innovative cancer therapies for patients.

Experts discuss the importance of transitioning cancer care from academic centers to community settings, ensuring effective patient management and support.

Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient support and effective communication.